S&P Futures
4,057.25 -27.00 (-0.66%) Dow Futures
33,869.00 -177.00 (-0.52%) Nasdaq Futures
12,117.50 -104.75 (-0.86%) Russell 2000 Futures
1,906.40 -13.10 (-0.68%) Crude Oil
79.14 -0.54 (-0.68%) Gold
1,938.60 -7.00 (-0.36%)
After hours:
Chart Events
Performance Outlook
| Previous Close | 348.01 |
| Open | 346.11 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 1000 |
| Day's Range | 341.53 - 348.09 |
| 52 Week Range | 231.87 - 384.44 |
| Volume | |
| Avg. Volume | 2,830,577 |
| Market Cap | 325.056B |
| Beta (5Y Monthly) | 0.38 |
| PE Ratio (TTM) | 51.44 |
| EPS (TTM) | 6.65 |
| Earnings Date | Feb 02, 2023 |
| Forward Dividend & Yield | 4.52 (1.32%) |
| Ex-Dividend Date | Feb 14, 2023 |
| 1y Target Est | 389.56 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for LLY
Related Research
- Eli Lilly and CompanyAnalyst Report: Eli Lilly and CompanyEli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.RatingFair ValueEconomic Moat10 days agoMorningstar
- American City Business Journals
Why Eli Lilly is tagging the Research Triangle for long-term growth
Pharmaceutical giant Eli Lilly is planting the seeds for a long-term commitment in Research Triangle Park.
- Reuters
UPDATE 1-FDA approves Eli Lilly's blood cancer drug
Eli Lilly and Co said on Friday the U.S. health regulator approved its drug for the treatment of a rare form of blood cancer. The Food and Drug Administration gave accelerated approval to Jaypirca for the treatment of adults mantle cell lymphoma after at least two lines of therapy.
- PR Newswire
U.S. FDA Approves Jaypirca™ (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma After at Least Two Lines of Systemic Therapy, Including a BTK Inhibitor
Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that the U.S. Food and Drug Administration (FDA) approved Jaypirca™ (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor. Jaypirca was approved under the FDA's Accelerated Approval pathway based on response rate from the open-label, single
